Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks petemantx, I believe!
Go Leo & IPIX!
Agree completely. Leo laid it on the line that deals would follow completion of P2 trials, which we must interpret to include analyzing the data and releasing the results, and that should come about shortly. Shortly means many things to each of us so whether that be a few days, a few weeks, a few handful of weeks, or a few months no one knows.
All the pleading and tearing out of hair for an immediate deal is nothing more than FUDster gamesmanship to make it look like mgt isn't moving things forward, when time and again over the last year Leo has showed that is not the case.
Though the clinical trial system of progress seems to move at an iceberg pace to overanxious stockholders, the good thing about it is one knows exactly where they stand in terms of time to completion based on patient enrollment rate, time last patient in trial started treatment, length of medication, followup interval, and finally an unknown but good estimation on analyzing the data and putting forth the results. Right now we are in the analyzing data stage and have a good idea we are within a number of weeks til they come out. Just when will never be known til data released, so pleading for a faster time frame serves no purpose other than to play into the FUDster's hands of trying to identify a problem that is just not there.
The main question is once we get data, how long then? We know Leo has been in contact with multiple BPs, but we know nothing as to how far along any talks have reached regarding bringing a deal to be signed. Has a partnership price been reached depending on strength of data, will pricing only begin once data is released, are new BPs coming on board to cause a restart in the negotiation process, etc, etc?
Either you believe Leo is getting the job done as quickly as possible according to the tenets he has stated for and deal or you don't. If you believe, the best support you can give is silence during this period. If you don't believe, you continue to bring up historical nonsense from years past, reiterate the current stock price on an hourly basis (even though everyone knows why price is low), and keep up the chant of "The sky is falling".
Think of the monies involved here. A deal is not going to happen overnight, not when you are dealing in Billions.
George,
Can't wait!
Go Leo & IPIX!
Is there ABSOLUTELY GREAT NEWS on the HORIZON???
Good luck and GOD bless,
I agree, IMO Prurisol is well on its way for huge success. In fact, all of IPIX drugs are destine for huge success.
I love the Prurisol phase 2a data. It’s funny, I bet that this trial and results spark an epic run while everyone is dogging it and saying it’s so bad.
Great article about short attacks.
https://totalwealthresearch.com/2015/06/how-to-handle-a-short-attack-on-a-stock-you-own/
How to Handle a Short Attack on a Stock You Own
Keith Fitz-Gerald Jun 03, 2015 67
An anonymous individual writing under the name “The Pump Stopper” launched a vicious attack on Ekso Bionics Holdings Inc. (OTC:EKSO) yesterday that immediately pressured the stock and caused it to drop 24.28% to close at $1.36 a share on heavy volume. Understandably, that makes a lot of people nervous.
Here’s the thing, though.
If you’ve been in this game long enough, you know what to look for and why stuff like this isn’t a big deal in the scheme of things.
Today we’re going to talk about how to recognize a legitimate short versus a short attack and what to do about it, especially when it comes to a stock you may own like Ekso.
Here’s what you need to know:
First, let’s tackle the elephant in the room – stock manipulation.
Most investors are familiar with the phrase “pump and dump.” That’s what the SEC calls a form of financial fraud used to artificially inflate the price of a stock – usually a small-cap or microcap – for personal gain by distributing misleading and false statements. That’s the pump.
The dump comes later when the fraudsters suddenly sell their stock en masse and the price drops catastrophically, causing investors to lose their money.
It used to be done in so-called boiler rooms or small back offices like those depicted in the film The Wolf of Wall Street, but now it’s most commonly perpetrated via the Internet and chat boards. Pump and dump is so extensive that these kinds of stock scams may now account for an estimated 5-15% of all spam email.
It’s blatantly illegal.
The reverse of that is called “short and distort.” That’s what’s happening with Ekso.
Instead of buying the stock in question, the perpetrators typically short the targeted company first, then release theoretically independent reports and analysis that is little more than a thinly veiled smear campaign. Once the stock has fallen, the parties involved buy to cover, bank their profits, and hopefully disappear.
This, too, is illegal, but that doesn’t change the fact that it happens all the time.
Sadly, the SEC is totally outclassed and seemingly always a step behind. They simply don’t have the resources to detect, prosecute, and punish every short and distort artist out there.
Many people wonder how this is possible, especially today. It’s not as difficult as you would think.
TV personality Jim Cramer gave a hair-raising interview in December 2006 that was aired in March 2007, describing how hedge fund managers and others push stocks higher or lower at will, stating specifically that some hedge fund managers spread false rumors to drive a stock down.
“What’s important when you are in that hedge fund mode,” he noted at the time, “is to not do anything remotely truthful because the truth is so against your view, that it’s important to create a new truth, to develop a fiction.”
Then he outlined three ways to do that:
1) Spread false rumors
2) Drive futures
3) Give information to reporters who would then spread the “news” giving it an air of legitimacy
So how do you recognize legitimate shorting versus a short “attack” or even a bluff?
There are a few giveaways:
First, real short sellers don’t hide behind anonymous Internet chat boards and cutesy names. They don’t have multiple email accounts to engage in rumor mongering. And they don’t have websites registered in Panama that have been through nine changes hosted on seven different name servers over the past eight years. That’s because guys like George Soros, Simon Cawkwell, Mark Cohodes, and Jim Chanos – some of the most famous legitimate and successful short sellers of our time don’t need to. They’re idea-driven.
Second, real short sellers don’t want attention. In fact, they want the exact opposite – not to tip anybody off so that they have an extended period of time to maximize their positions. “Short and distort” sellers typically use high volume activity to drive prices down quickly in their own self-interest rather than see them collapse under their own weight.
Third, real short sellers publish factual information if they publish anything at all. Short and distort artists string together information that may or may be germane, let alone accurate under the guise of personal opinion that makes it hard to prosecute. They rely on selected information that is taken out of context or partial truths and inference. Ethics have very little to do with how they play the game. Their sole interest is in creating short term angst that causes investors to bail so that they make money buying depressed shares.
Obviously, this is not pleasant for anybody. Short and distort artists prey on panic. They have a demoralizing effect that can hurt not only individual investors but also the companies they target by slowing down financing and growth.
Believe it or not, though, there is a silver lining.
Sometimes short sellers get burned by their own mojo. If enough people come back into a stock, that pressures the short sellers who are then forced to cover at higher prices in something called a “short burn.” The irony is that many times it’s their own actions that light the fire.
The other thing to think about is that if you buy off on the targeted company’s potential – in this case Ekso – a short attack can be a super time to pick up shares that are temporarily “on sale.”
Speaking of which…
What’s Happening with Ekso
Less than an hour after I learned about the story, I was on the phone with Ekso’s CEO Nathan Harding and CFO Max Scheder-Bieschin. As you might imagine, I share your concerns given the very serious nature of the allegations being made. So, I was keen to speak with them.
I learned that the company will be issuing a point-by-point rebuttal to The Pump Stopper and that it will be posted on Ekso’s website as soon as possible. That way all interested parties – investors and “The Pump Stopper” alike – will have access to it at the same time.
This is absolutely consistent with what you would expect from a public company in Ekso’s position and in full compliance with SEC regulations, including FD, Rule 10b5-1 and Rule 10b5-2 governing the release of material non-public information.
The Way to Defeat “Short and Distorts” Is by Keeping Perspective
I’ve studied Ekso carefully, reviewed competitive offerings carefully, visited headquarters and, talked extensively with C-level executives, Ekso users, and even health care professionals.
To be very clear, I saw and still see tremendous potential ahead.
Short attacks like this are unfortunate and gut-wrenching. But they come… and they go.
“The Pump Stopper’s” allegations seem credible at first glance, but many of them don’t make sense if you stop and think about them logically for a minute.
Take the allegation that Ekso’s testing centers now prefer competitive products, for example. These are the top treatment centers in the world. It’s not in their interest to be exclusive with any manufacturer… not Ekso, not ReWalk, not Cyberdyne. You could easily substitute their names instead of Ekso’s and instantly those companies would be on the defensive.
Instead, what these treatment centers want is to evaluate and use as many options as possible. They have a medical obligation to their clients to test any device with potential. That way they can offer the broadest spectrum of treatment.
Ekso has never communicated a goal to be the only one there, nor have they claimed that Ekso suits work on all patients. That’s an inference “The Pump Stopper” hopes you’ll make so you’ll hit the sell button and make HIM money.
Or how about the list of employee defections?
People come and go all the time, so employment ebbs and flows with every startup, not just Ekso. This isn’t unusual if you understand how Silicon Valley startups work.
Further, according to CFO Max Scheder-Bieschin, many of those same people are actually working at Ekso again at this very moment. The Pump Stopper doesn’t want you to know that because that interferes with HIS agenda.
Obviously, this situation is a long way from over, which is why I am watching it carefully. There may be more selling ahead. In fact, I’d bet on it.
But what I wouldn’t do is abandon ship in a panic.
We’re talking about a stock that’s between $1 and $2 a share. It’s not like we’re talking about Netflix at $624 a share here. So your downside is limited.
That said – to be really blunt – if you cannot handle the loss of $0.37 a share, you have no business investing in the stock market let alone a startup company like Ekso. Investing is risky and all investments can lose money. That’s why you never, ever invest money in any stock that you can’t afford to be without.
Further, if you’ve taken emotion out of the equation and properly position sized your investments, including Ekso, in keeping with the Total Wealth Tactics we’ve discussed many times, you’re not going to blow up your portfolio if something goes wrong.
And, finally, keep my original instructions in mind. Ekso is a long-term investment that will be volatile. Startups always are. That’s why my original instructions were to average down if the stock fell to $0.75 per share. Barring any change in the material information that Ekso releases shortly regarding The Pump Stopper’s allegations, those still stand.
Still, I know this is tough. Nobody likes to see a stock they believe in get clobbered for any reason… but keep it in perspective.
Microsoft is on track to do $99.3 billion in global revenue for 2015. In 1976, it booked $16,005.
Many times stocks that are ultimately big winners feel frail in the beginning.
Best regards,
Keith
https://totalwealthresearch.com/2015/06/how-to-handle-a-short-attack-on-a-stock-you-own/
IPIX is amazing... Great post and thanks for taking the time to do this.
Well, Infinity, actually they did tell us something.
I just takes an effort to lift ones mental ass off from the whiny chair and do something called estimating. Lemme show you how:
We know that there were 6 subjects (0.462 * 13 = 6) in prurisol 200 mg group with IGA 3 that had 2 point drop. Numbers for 200 mg ITT group were 28 subjects and 18 of them were IGA 3. Let's be stingy and assume that the seventh 2 point drop in ITT did not happen in IGA 3 group. We get:
prurisol 200 mg ITT IGA 3 - 2 point change percentage: 100*6 /18 = 33.3 % (at least)
Placebo group had ITT of 30 out which 23 was IGA 3. This group had 4 subjects with 2 point IGA drop. Let's be generous and assume that all four happened in IGA 3 subjects. That means
placebo ITT IGA 3 - 2 point change percentage: 100*4/23 = 17.4 % (at most)
Risk ratio associated with 2 point drop in IGA 3 groups: 0.52 for prurisol (and probably better). A number that is known to imply clear statistical significance in 100+ subjects trials.
BTW:In Esteem 2 trial Otezla scored PASI 75 percentage of 28.8 % when calculated using LOCF. Prurisols results in p2a are probably better than that. Strange: It looks like Leo did not lie, but famous Adam F. might have. Who would have thunk THAT!
petemantx,
I have a very good friend in his mid 50's who has suffered with Ulcerative Colitis for most of his adult life. It affects him every hour of the day and every day of the year. I was absolutely astonished when I saw that slide of how B cleared up those GI tracts and literally had to show him. He would pay large amounts of money to be cured from this.
I really hope that the IPIX drug line can someday help people like my friend.
Go Leo & IPIX!
I am not a medical person but in delving into OM, Crohns Disease, and IBD it appeared to be that there were many similarities between the three of them. The major difference I garnered is that IBD, to include Crohns and Ulcerative Colitis (UC), is a natural occurrence usually affecting people starting at the age of 15-25 and it becomes a chronic problem for life as it is the body's own immune system attacking the tissue in the GI tract. Since UC is contained only in the large intestine and rectum, it is Crohns that would occur in the mouth and throat. OM is caused by radiation/chemotherapy but results in the same type of sores as does Crohns but these symtoms go away in time (usually a matter of weeks) since the immune system hasn't turned against the body and thus goes away as the residual chemo/rad affects on the skin and tissues go away.
I have heard the board chatter about the horrors of OM but little about the horrors of IBD, especially Crohns, as I consider Crohns to be like UC on steroids, and thus not only is the mouth/throat causing a problem but the whole GI tract is a problem, even though not the whole GI tract is usually affected with sores. I hope people realize how life-altering IBD, UC, and Crohns is and what a wonderful gift Brilacidin should be to the world in greatly erasing/easing the problems of all those w/ OM, UC, IBD, and Crohns.
TB,
You may have missed this post from petemantx. See below, I think it nicely answers your statement.
Perhaps if shareholders dug around and got a clearer picture of the true status of IPIX, they would run for the hills.
Leo can't have that.
petemantx Monday, 01/08/18 06:06:46 PM
Re: loanranger post# 212002
Post #
212004
of 212037 Go
IMO this show is only good for the contacts made and the one-on-one sessions the company is involved in both here and across the street at the JPM show as well.
They aren't presenting anything that hasn't already been released so the show may be extremely positive but the shareholders won't hear about it as it will do with upcoming deals or financing. IMO
Thanks for some FACTS sox040713,
Go Leo & IPIX!
BP's interests in the Big Three
"To advance our pipeline in an expeditious manner, this year we placed an emphasis on partnering—actively engaging global and regional pharmaceutical companies interested in licensing our novel drug candidates. These efforts have led to highly productive, mature (late-phase, ongoing) discussions, with multiple pharmaceutical companies, which we hope will bear fruit in the coming year." - CEO Letter to Shareholders
"We had said that confidential disclosure agreements have been signed with several pharmas interested in our drug candidates; to some, they're interested in one compound. Others have requested information on a combination of Brilacidin and Kevetrin and Prurisol."
https://seekingalpha.com/article/4080068-innovation-pharmaceuticals-ipix-ceo-leo-ehrlich-q3-2017-results-earnings-call-transcript
B-OM
“Formal collaboration with pharmaceutical companies that have expressed an interest in partnering Brilacidin-OM may well assist further with expediting the drug candidate’s development timetable. Some of these partnering conversations have matured to the point of potentially structuring mutually beneficial licensing agreements, pending the final Phase 2 study results.”
http://www.ipharminc.com/press-release/2017/11/16/innovation-pharmaceuticals-offers-perspectives-on-brilacidin-as-a-potential-preventative-treatment-for-oral-mucositis-in-head-and-neck-cancer-patients
B-UP
"We've actively engaged with multiple large pharmas, who have expressed an interest in Brilacidin inflammatory bowel disease. The pharma industry is quite interested in pursuing novel IBD therapies one of the more active therapeutic areas when it comes to dealmaking."
https://seekingalpha.com/article/4080068-innovation-pharmaceuticals-ipix-ceo-leo-ehrlich-q3-2017-results-earnings-call-transcript
Prurisol
"We have entered into multiple non-disclosure agreements with large pharmaceutical companies that enable us to continue ongoing discussions regarding potential partnering should the trial results support such a relationship."
https://www.sec.gov/Archives/edgar/data/1355250/000147793217004400/ipix_10k.htm
Kevetrin
"What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,"
http://www.ipharminc.com/press-release/2017/9/14/innovation-pharmaceuticals-opens-new-clinical-site-for-novel-p53-drug-candidate-in-phase-2-ovarian-cancer-trial-1
petemantx,
Outstanding post! It really assisted me with understanding Kevetrin.
Go Leo & IPIX!
It is reassuring that the creator of Kevetrin already has played a key role for two successful drugs, Gemzar and Alitra, on the market thru E I Lily, that fight cancer. He knows cancer inside and out and has stated many times his belief that Kevetrin will become a standout product.
There will always be a widespread need for many cancer drugs, so no drug will be direct competition for Kevetrin, but more likely complementary treatments for various types of cancer.
Kevetrin has shown to work against both mutant and wild p53, so it is not like some competitor is going to be able to make K obsolete no matter what they can do. As an aside, in regards to what I see as being the alternative drugs being compared to Kevetrin that are being touted on the board, they are far and away at a riskier state of development as Kevetrin as one or two aren't even out of pre-clinical trials yet so even mentioning them as competitors is a joke at the current time.
What I feel is THE KEY to the power of Kevetrin is its ability to be used as a combo treatment with other cancer fighting agents. Many years ago I heard (can't remember exact source) that if Kevetrin was to be compared to ingredients in a kitchen, it would be most akin to salt or sugar in that it can be combined with nearly everything. To be great in itself is wonderful, but to be able to make all other cancer treatments more effective is beyond the pale. It is this feature that will make Kevetrin the #1 choice for research on compound treatments for a wide, wide range of oncology products and will establish Kevetrin's place at or near the top of cancer products worldwide.
Dud,
IMO, I think you are on the wrong board. IPIX does not sell pigs?
However, IPIX is currently working on a deal to partner one of these three drugs which may happen sooner than later.
PRURISOL
Oral psoriasis drug candidate in a Phase 2b trial utilizing the advantages of 505(b)(2) development approach
KEVETRIN
Orphan-designated p53-modulating drug candidate in a Phase 2a trial for late-stage ovarian cancer
BRILACIDIN
An immunomodulatory drug candidate with anti-inflammatory and antibiotic properties granted Fast Track status
Go Leo and IPIX!
DaubersUP,
Absolutely awesome post! Please keep it coming...
Go Jags, Leo & IPIX! lol
It is amazing how the mood here has been set by several that IPIX MGMT is in any sort of desperate situation based off share price. The word "begging" has been thrown around and the idea that IPIX 'NEEDS' to take a deal, just to take a deal...It is the most absurd idea and furthest from the truth.
For new investors or readers on this site looking into IPIX, do your DD on IPIX website and reach out to the company if you have questions.
Here is a little Sunday morning DAUB opinion:
The share price is at a low and for reasoning that can be discussed in a completely separate post. This is a highly unknown Bio Tech and resides on the OTCBB lacking major institutional buyers.
Here are some scenario's.
IPIX has 3 major drugs! Each of those drugs have several multi-billion indications opportunities. Each of those drugs are in mid-late stage clinical trials. The share price is at an extreme low for the pipeline and progress. For example, having B-Absssi (1 Day IV) sitting at a phase 3 start where that drug proved to be just as effective as Dapto (7 day IV) should warrant the current market cap and most likely have a higher market cap just for B-Absssi. IMO Dapto pulls in over a billion dollars a year.
Lets add B-OM where we just received extremely promising data for a phase 2 trial where this currently NO approved preventative SOM drugs on the market and the market is estimated to be anywhere from 1 - 2 BILLION dollars. Again there are NO current preventative SOM drugs. That alone should spur a several hundred million market cap as we secure a possible BREAKTHROUGH DESIGNATION in the upcoming months and secure our first partnerships.
Don't forget about B-UP/UC - this market is one of the most lucrative for IPIX as they add oral formulation for Crohns and UC. The data from the B-OM data just anchors this UP foam/water enema which alone could bring in 100's of thousands alone. Add different formulations and we are in the multi billions easily. IMO.
Not to mention Prurisol the dark horse, for Psoriasis. An ORAL drug for Psoriasis that has now completed it's phase 2b trial using the same criteria that Otezla did using the PASI scale. Remember OTEZLA is a blockbuster with major side effects and limited efficacy. The bar is set atleast - like 32% PASI 75. That is what we are looking for. I say lets go get 40% PASI 75 and this company should hold atleast a 5 billion market cap over night. IMO If the dark horse is proves even better, watch out BIOLOGICS ----- Psoriasis is close to a 10 BILLION market.
Kevetrin is why most of us arrived here. Years ago it was all speculative that CTIX/IPIX had a drug that could potentially reactivate the P53 gene - both wild-type and mutant. TP53 gene is the "HOLY GRAIL" of the human genome scientist say. They also say that it is affected in more than 50% of all cancers. The development has been steady and the phase 1 trial was extremely successful however it took a very long time to complete because Kevetrin was just too safe and they could not reach an MTD. Going from 10mg/m2 to 750mg/m2 took several years until they just decided to end the trial as the curve IPIX saw showed there was not much more benefit from that high of a dose. The fact that they saw p21 expression in the phase 1 and it was safe and they actually saw tumors disappear is a milestone and result that has been swept under the rug for I-Hub investors as the noise is much louder here. BP steps in and advises IPIX to go a different route in a phase 2a for Ovarian Cancer looking for more proof of modulation and MOA - and we just read the first data read outs for the first couple patients and they saw exactly what they were looking for. That alone - minus all other drugs and progress should give us a 5X market cap from where are on speculation that we could have the most sought after Cancer drug in the history of drugs. IMO>
But again, we are an OTCBB where 99% of the world has never heard of IPIX. The only people that know about IPIX are day traders and some small retail investors that read iHUB ----
IPIX does not need to beg for anything. They have "MULTIPLE CDA's" for all drugs. As they have said, some BP's are looking at one drug, some BP's are looking at all drugs, etc... The minute one BP sleeps or drags their feet is an opportunity for another BP to capitalize on these highly effective drugs. The potential here is 10's upon 10's of BILLIONS of dollars and the market cap will reflect that just like other major Bio's.
I went back and read a board for a major Bio that was bought out in 2015 and read the board going back to 2007 and looked at the price and comments over that span and what the company was achieving and compared to us here. I am in awe at our share price, however just like them going from like .55 to 261 and being bought for 21 Billion dollars, I believe our pipeline by far trumps anything close to theirs.
Over the next years, I think we will see the movement they saw going quickly from cents to 10 - 40 - 90 - dollars.
Again - there is no need for begging from anyone here at IPIX --- we are in the best shape we have ever been. We have Aspire and about 28million in financing and a 75 million shelf to raise funds if needed to go alone a drug or two. However, as LEO has stated, last years focus was partnership and they are close and in late stage negotiations so I assume we will put Aspire on the shelf at some point this year and many will need to cover their short positions as we wake up to a watershed moment where people will be out millions of dollars as IPIX's value is reassessed and the true value is unlocked. IMO
Lets go JAGS! and IPIX
Detonate,
Very good questions - I am also confused with that post!
Go Leo & IPIX
I tried following today's effort at plumbing new depths but got lost and am asking for clarification.
Are you saying that IPIX currently owns/drives a car, is married, and is gainfully employed?
Or is this referring to an individual who, although having "3mm in the bank for IPIX", is at risk of not meeting monthly living expenses?
Quote:
3mm in the bank for ipix. One car accident, divorce, or period of unemployment and it’s hello living under the bridge.
Numbers don't lie! Please read new investors. These are the facts from IPIX website about their financial situation. Please do your DD, this is not a dire situation as implied by some posters on his board.
http://www.ipharminc.com/financials/
http://www.edgarmaster.com/Inet/main/DataFeedHtml1.jsp
Go Leo & IPIX!
58nout,
I agree 100%. This company could not be headed in a better direction. IPIX has had their share of attacks over the years but as we all know, hard knocks and challenges in life make us stronger and that's what I think IPIX had to go through. Once we get the Prurisol and BOM results we will be off to the races. That will set us up nicely for a partnership and then the NASDAQ.
Go Leo & IPIX!
IPIX has no debt, no debt, no debt, no debt, no debt and no debt.
Debt has killed many a company. One doesn't have to search far from here to see that the former owner of IPIX's most promising compound was killed off by not being able to make the required interest payment on it's heavy debt load, that being Polymedix. Creditors just don't care and BTW for those that like to throw around the term toxic financing, they have it ass backward. In the Polymedix example, the financing was not toxic to Polymedix but to the creditor who got caught holding the bag.
Leo Ehrlich's use of just-in-time financing via the Aspire deals totaling 90 million dollars has been truly exceptional. It fits perfectly for those who hold a long term view of their investment, and for those with a short term view, not so much.
I don't know about how others feel, but I've been in heavy debt with mortgages, college tuition, equity loans, credit cards and it suffocates you. Your hands are always tied. It's nice to be out of it.
The beauty of IPIX not having any debt allows it to run the company and make sure that whatever deals it makes, they'll be right for the shareholders and not deals that they're forced into prematurely. Not realizing the true value of their assets and thereby shortchanging the long term investors, is and always should be avoided at all costs. I'm a fan.
GO IPIX - stay the course
IPIX has very meaningful science!
I am excited to see what the Monday conference brings us longs!
Go Leo & IPIX
http://www.ipharminc.com/
PRURISOL
Oral psoriasis drug candidate in a Phase 2b trial utilizing the advantages of 505(b)(2) development approach
KEVETRIN
Orphan-designated p53-modulating drug candidate in a Phase 2a trial for late-stage ovarian cancer
BRILACIDIN
An immunomodulatory drug candidate with anti-inflammatory and antibiotic properties granted Fast Track status
petemantx,
Very good points and I agree "Brilacidin has too much unknown potential".
I am getting super exited about next weeks conference.
Go Leo & IPIX!
Brilacidin has too much unknown potential to even consider dealing it out complete now. Prurisol makes much more sense as a generator of immediate cash and strong back end royalty payments since it is more of a one trick pony (psoriasis) with the further possibility of psoriatic arthritis and the same BP could handle both of those indications.
B-OM may be partnered out but the entire IBD platform will be held tightly as well as the dermatology platform until a more complete understanding of how versatile B will prove to be is understood.
No chance of partnering out K right now as that is Dr. M's baby.
All above my opinion only.
cybermich,
You have some very valid points. With the current IPIX drug line up I suspect BP could be interested in any of them. BOM might be the first or will PRURISOL.
2018 = NASDAQ
Go Leo & IPIX!
Imo the main question a new investor should ask themselves..
will shares be more or less expensive after the first partnership is announced?
expect more "color" on Bom primary and secondary in the upcoming Jan 8th conference.
Will the first partnership be for just Bom?.. or will it include a deal for the entire B platform? (if its for the entire B platform the risk of being out of this stock could be much higher)
Imo a partnership is inevitable..
therefore buying at these levels is a "no brainer"
Good luck to all REAL IPIX investors.
Fact: IPIX has not even come close to failing any of their phase trials for any of their 3 drugs.
Go Leo & IPIX!
RELEASE
January 3, 2018
Innovation Pharmaceuticals Brilacidin Meets Key Secondary Endpoint in Phase 2 Trial, Delays Onset of Severe Oral Mucositis (SOM)
Brilacidin
Latest Results Further Support Topline Data Showing Trial Met Primary Endpoint of Reducing Incidence of SOM
BEVERLY, MA – January 3, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today presented additional secondary endpoint topline results from the Company's randomized, double-blind, placebo-controlled, Phase 2 clinical trial of Brilacidin (see NCT02324335) for the prevention and control of Oral Mucositis (OM) in patients receiving chemoradiation for treatment of Head and Neck Cancer.
Previously released results from the study showed the use of Brilacidin-OM met its primary endpoint with a clearly reduced incidence of severe OM (SOM) (WHO Grade ≥ 3) compared to placebo. Brilacidin-OM is being developed with global patent protections under an FDA Fast Track designation for this indication.
Summary of Key Secondary Endpoints Analysis
· Onset of Severe Oral Mucositis: Based on Kaplan-Meier curves, Brilacidin-OM oral rinse showed a clear separation from placebo in delaying the onset of SOM—particularly the period from approximately 28-42 days, after the initiation of treatment, during which the incidence of SOM rose strikingly in the placebo group while not in the group being treated with Brilacidin. The delay of onset of SOM data further support the positive primary endpoint findings that showed a clear reduction in the incidence of SOM in patients receiving Brilacidin-OM treatment. Our updated Corporate Overview, with a visual display of the Kaplan-Meier curves, is now available (pdf) on the Company’s website.
· Duration of Severe Oral Mucositis: Given that Brilacidin-OM successfully prevented SOM from occurring, as well as delayed its onset, in a substantial number of patients, data comparisons aimed at assessing potential reduction in the duration of SOM were constrained by the fewer number of Brilacidin-OM treated patients that could be included in such analysis. While Brilacidin-OM appeared to decrease the initial duration of SOM (time from the initial WHO Grade ≥ 3 to the first WHO Grade ≤ 2 OM assessment), detailed interpretation of this and other duration data comparisons were limited.
“The notable effect of Brilacidin-OM in delaying the onset of SOM in patients—on top of preventing it—further substantiates the drug candidate’s potential to emerge as a highly efficacious, safe and easy-to-administer preventative medicine for this notoriously painful and difficult-to-treat condition,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “That Brilacidin performed so well in this clinical trial puts us in an extremely advantageous position in both a competitive and regulatory sense. The unmet medical need in OM is tremendous and we look forward to advancing Brilacidin-OM toward possible market approval, which would help improve the lives of so many cancer patients.”
The Company is now working to complete the Clinical Study Report (CSR). The CSR is central for engaging with the FDA to further discuss program development, and is also an important component for informing already advanced OM partnership discussions. In Brilacidin-OM, based on the strong positive Phase 2 clinical results, the Company believes it has a highly promising and unique late-stage OM drug candidate that, with approval, could assume the leadership position in a market with untapped economic potential. The global OM market is expected to exceed $1 billion in the next few years.
Biotech Showcase Details
The Company will be presenting at the 2018 Biotech Showcase Investor and Networking Conference, held January 8-10, in San Francisco, as detailed below:
Date: Monday, January 8, 2018
Time: 4:00 PM PST
Track: Yosemite - C (Ballroom Level)
sox040713,
Thank you for the aspire financing clarification. This makes sense...
Go Leo & IPIX!
This one is too easy to refute. IPIX has enough financing for the next 12 months.
“As of September 30, 2017, we had approximately $2.9 million in cash compared to $4.1 million of cash as of June 30, 2017. We anticipate that future budget expenditures will be approximately $15 million for the next twelve months, including approximately $10 million for clinical activities, supportive research, and drug product development.”
“During the period from September 6, 2017 to September 30, 2017, the Company has generated proceeds of approximately $0.4 million under this agreement with Aspire Capital from the sale of approximately 0.6 million shares of its common stock. As of September 30, 2017, the available balance is approximately $29.6 million.”
“The Company has an effective shelf registration statement on Form S-3, registering the sale of up to $75 million of the Company’s securities. The Company filed the Form S-3 with the SEC on September 11, 2017, which included registering the shares underlying the 2017 $30 million Aspire Capital stock purchase agreement.”
https://www.sec.gov/Archives/edgar/data/1355250/000147793217005408/ipix_10q.htm
I’m glad there’s no lender so IPIX has no debt, which means they can’t file for bankruptcy.
“Bankruptcy is a legal status of a person or other entity that cannot repay debts to creditors.”
https://en.m.wikipedia.org/wiki/Bankruptcy
farrell90,
Awsome summary and reminder.
Thank you!
Go Leo & IPIX!
IPIX will be pounding the FDA's door for Break Through Designation.
Brilacidin for Oral Mucositis touches all the bases laid out by the FDA for Break Through Designation:
-Effective treatment is not currently available
-Two solid FDA phase studies for Brilicidin completed
-Great safety profile
-Easy dosage and application as an oral rise
Plus it will be used as a preventative treatment
The real reason Brilacidin will be approved is because Oral Mucosiditis is a miserable, painful, debilitating problem which complicates all aspects of care for cancer patients without any current effective treatment... until now.
OM complicates cancer treatment. Many patients have their treatment delayed or suspended.
OM interupts their nutrition at a time when good nutrition is imperative for their survival. It can even result in the need for Gastric feeding tube placement.
OM is psychologically devastating to cancer patients and can lead to patients deciding to stop all treatment..
An effective treatment for Oral Mucositis has to be a key goal for cancer care.
The FDA is very aware of its importance and the lack of current effective treatments.
Good luck, Farrell
updated from my earlier post 206478:
sox040713,
Thank you for working so hard on this board today and presenting factual information that posters can understand and rely on.
I really appreciate your efforts...
Go Leo & IPIX!
"The time needed to write the CSR generally depends on the complexity of the study design and the size of the data package. How long it will take to write will also depend on the experience and ability of the writer. It is therefore difficult to predict exactly how long a report ‘should’ take to write."
http://www.niche.org.uk/asset/insider-insight/Insider-Clinical-Study-Reports.pdf
The CSR is a very long document, but IPIX can get a head start by writing the shell first. From the same source,
Documents that are useful when writing the shell include:
• Relevant report template
• Final protocol and protocol amendments
• File notes (notes explaining specific incidents during the study)
• Study Procedures/Study Reference Manual
• Statistical/Reporting analysis plan
• Details of ethics committee, monitor, laboratories, etc
• Sponsor report writing SOPs/style guides
Now they can import the trial data package into the report and write the analysis and conclusion section. This isn't IPIX's first rodeo so I don't expect it to take long. The CSR should be the last piece of information (from IPIX) to the FDA for applying BTD and to the potential partner for a deal.
Quote:
Does anyone here know how long it could take to complete the CSR,..?
petemantx,
Another great analogy!
Go Leo & IPIX!
Your view is slanted as you are mainly a flipper/trader (not criticizing, just making a statement) and work on making pennies to small amounts on your trades. That has to slant your views for quick turnaround in your holdings IMO.
B-OM is the only proven cure for a very serious condition affecting a large population and has shown remarkable results, results that can only be improved by tweaking the delivery method down the line.
To downplay what we own to the degree you state is laughable. A Lamborghini is just a car as is a Prius, but quite a difference in value. You value Brilacidin-OM as a Prius while longs view it as a Lam...
IPIX Release - Nothing to yawn about!
January 3, 2018
Innovation Pharmaceuticals Brilacidin Meets Key Secondary Endpoint in Phase 2 Trial, Delays Onset of Severe Oral Mucositis (SOM)
Brilacidin
Latest Results Further Support Topline Data Showing Trial Met Primary Endpoint of Reducing Incidence of SOM
BEVERLY, MA – January 3, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today presented additional secondary endpoint topline results from the Company's randomized, double-blind, placebo-controlled, Phase 2 clinical trial of Brilacidin (see NCT02324335) for the prevention and control of Oral Mucositis (OM) in patients receiving chemoradiation for treatment of Head and Neck Cancer.
Previously released results from the study showed the use of Brilacidin-OM met its primary endpoint with a clearly reduced incidence of severe OM (SOM) (WHO Grade ≥ 3) compared to placebo. Brilacidin-OM is being developed with global patent protections under an FDA Fast Track designation for this indication.
Summary of Key Secondary Endpoints Analysis
· Onset of Severe Oral Mucositis: Based on Kaplan-Meier curves, Brilacidin-OM oral rinse showed a clear separation from placebo in delaying the onset of SOM—particularly the period from approximately 28-42 days, after the initiation of treatment, during which the incidence of SOM rose strikingly in the placebo group while not in the group being treated with Brilacidin. The delay of onset of SOM data further support the positive primary endpoint findings that showed a clear reduction in the incidence of SOM in patients receiving Brilacidin-OM treatment. Our updated Corporate Overview, with a visual display of the Kaplan-Meier curves, is now available (pdf) on the Company’s website.
· Duration of Severe Oral Mucositis: Given that Brilacidin-OM successfully prevented SOM from occurring, as well as delayed its onset, in a substantial number of patients, data comparisons aimed at assessing potential reduction in the duration of SOM were constrained by the fewer number of Brilacidin-OM treated patients that could be included in such analysis. While Brilacidin-OM appeared to decrease the initial duration of SOM (time from the initial WHO Grade ≥ 3 to the first WHO Grade ≤ 2 OM assessment), detailed interpretation of this and other duration data comparisons were limited.
“The notable effect of Brilacidin-OM in delaying the onset of SOM in patients—on top of preventing it—further substantiates the drug candidate’s potential to emerge as a highly efficacious, safe and easy-to-administer preventative medicine for this notoriously painful and difficult-to-treat condition,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “That Brilacidin performed so well in this clinical trial puts us in an extremely advantageous position in both a competitive and regulatory sense. The unmet medical need in OM is tremendous and we look forward to advancing Brilacidin-OM toward possible market approval, which would help improve the lives of so many cancer patients.”
The Company is now working to complete the Clinical Study Report (CSR). The CSR is central for engaging with the FDA to further discuss program development, and is also an important component for informing already advanced OM partnership discussions. In Brilacidin-OM, based on the strong positive Phase 2 clinical results, the Company believes it has a highly promising and unique late-stage OM drug candidate that, with approval, could assume the leadership position in a market with untapped economic potential. The global OM market is expected to exceed $1 billion in the next few years.
Biotech Showcase Details
The Company will be presenting at the 2018 Biotech Showcase Investor and Networking Conference, held January 8-10, in San Francisco, as detailed below:
The IPIX corporate overview has been updated. As some of my fellow posters are constantly saying "TICK TOCK". Get it while it is cheap because it will not be cheap for much longer.
2018 = NASDAQ
Go Leo & IPIX!
http://www.ipharminc.com/s/2018Jan-IPIX-Corporate-Overview.pdf
January 3, 2018
Innovation Pharmaceuticals Brilacidin Meets Key Secondary Endpoint in Phase 2 Trial, Delays Onset of Severe Oral Mucositis (SOM)
Brilacidin
Latest Results Further Support Topline Data Showing Trial Met Primary Endpoint of Reducing Incidence of SOM
BEVERLY, MA – January 3, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today presented additional secondary endpoint topline results from the Company's randomized, double-blind, placebo-controlled, Phase 2 clinical trial of Brilacidin (see NCT02324335) for the prevention and control of Oral Mucositis (OM) in patients receiving chemoradiation for treatment of Head and Neck Cancer.
Previously released results from the study showed the use of Brilacidin-OM met its primary endpoint with a clearly reduced incidence of severe OM (SOM) (WHO Grade ≥ 3) compared to placebo. Brilacidin-OM is being developed with global patent protections under an FDA Fast Track designation for this indication.
Summary of Key Secondary Endpoints Analysis
· Onset of Severe Oral Mucositis: Based on Kaplan-Meier curves, Brilacidin-OM oral rinse showed a clear separation from placebo in delaying the onset of SOM—particularly the period from approximately 28-42 days, after the initiation of treatment, during which the incidence of SOM rose strikingly in the placebo group while not in the group being treated with Brilacidin. The delay of onset of SOM data further support the positive primary endpoint findings that showed a clear reduction in the incidence of SOM in patients receiving Brilacidin-OM treatment. Our updated Corporate Overview, with a visual display of the Kaplan-Meier curves, is now available (pdf) on the Company’s website.
· Duration of Severe Oral Mucositis: Given that Brilacidin-OM successfully prevented SOM from occurring, as well as delayed its onset, in a substantial number of patients, data comparisons aimed at assessing potential reduction in the duration of SOM were constrained by the fewer number of Brilacidin-OM treated patients that could be included in such analysis. While Brilacidin-OM appeared to decrease the initial duration of SOM (time from the initial WHO Grade ≥ 3 to the first WHO Grade ≤ 2 OM assessment), detailed interpretation of this and other duration data comparisons were limited.
“The notable effect of Brilacidin-OM in delaying the onset of SOM in patients—on top of preventing it—further substantiates the drug candidate’s potential to emerge as a highly efficacious, safe and easy-to-administer preventative medicine for this notoriously painful and difficult-to-treat condition,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “That Brilacidin performed so well in this clinical trial puts us in an extremely advantageous position in both a competitive and regulatory sense. The unmet medical need in OM is tremendous and we look forward to advancing Brilacidin-OM toward possible market approval, which would help improve the lives of so many cancer patients.”
The Company is now working to complete the Clinical Study Report (CSR). The CSR is central for engaging with the FDA to further discuss program development, and is also an important component for informing already advanced OM partnership discussions. In Brilacidin-OM, based on the strong positive Phase 2 clinical results, the Company believes it has a highly promising and unique late-stage OM drug candidate that, with approval, could assume the leadership position in a market with untapped economic potential. The global OM market is expected to exceed $1 billion in the next few years.
Biotech Showcase Details
The Company will be presenting at the 2018 Biotech Showcase Investor and Networking Conference, held January 8-10, in San Francisco, as detailed below:
Date: Monday, January 8, 2018
Time: 4:00 PM PST
Track: Yosemite - C (Ballroom Level)
Brilacidin is an amazing drug, please read below if you are not familiar with it.
http://www.ipharminc.com/brilacidin-1
BRILACIDIN
Brilacidin is Innovation's lead drug candidate in its defensin-mimetic franchise.
Modeled after Host Defense Proteins (HDPs), the “front-line” of defense in the body's innate immune system, it is a synthetic, non-peptidic small molecule that kills pathogens swiftly, significantly reducing the likelihood of drug resistance developing. Just as importantly, Brilacidin functions in a robust immunomodulatory capacity, lessening inflammation and promoting healing.
Innovation is evaluating Brilacidin, under Fast Track designation, in a Phase 2 clinical trial as an oral rinse to attenuate Oral Mucositis in patients with Head and Neck Cancer who have received chemoradiation. Topline study results indicate Brilacidin has a high potential for preventative treatment, as evidenced by a clear reduction of severe OM (SOM) among patients on Brilacidin as compared to those on placebo.
Innovation also is testing Brilacidin, administered with water in an enema, in patients with Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS) — a type of Ulcerative Colitis (UC), and, like Crohn's Disease, an Inflammatory Bowel Disease (IBD) — in a proof-of-concept Phase 2 clinical trial. Topline findings support Brilacidin as a novel, non-corticosteriod, non-biologic IBD treatment, with a majority of patients treated achieving induction of clinical remission. Formulation development plans include foam and/or gel for the treatment of UP/UPS and oral tablets for the treatment of UC and Crohn's.
As a mimic of HDPs, which play a key regulatory role in the etiology of skin diseases, and due to its limited systemic absorption when topically applied (a favorable pharmacokinetic profile), Brilacidin may have other applications in treating dermatological disorders. Additional trials of Brilacidin are planned in Acne, Hidradenitis Suppurativa and Atopic Dermatitis (Eczema).
A key aspect of Brilacidin's mechanism of action, inhibiting Phosphodiesterase 4 (PDE4), may further support its use in treating Asthma, Psoriasis, Psoriatic Arthritis and Chronic Obstructive Pulmonary Disease (COPD), alongside other chronic autoimmune conditions.
As an antibiotic, representing the first in a new class of anti-infectives, Brilacidin is being advanced in the clinic under Qualified Infectious Disease Product (QIDP) designation — qualifying the drug candidate for Fast Track and Priority Review, as well as an extra 5 years of market exclusivity upon drug approval. A Phase 2b trial was completed evaluating Brilacidin as an intravenously-administered medication in treating Acute Bacterial Skin and Skin Structure Infection (ABSSSI). Trial data showed a single dose of Brilacidin to be comparable in safety and efficacy to a 7-day dosing regimen of FDA-approved Daptomycin.
“BRILACIDIN [...] HAS A HIGH LIKELIHOOD OF REACHING COMMERCIALIZATION.”
— Dr. Michael Zasloff
Pre-clinical work has been conducted, as well, on the gram-negative, anti-fungal, biofilm and material applications of HDP-mimetic compounds.
Brilacidin and related compounds are protected under various composition and use patents. A patent was filed and is pending for the use of HDP-mimetics in the prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract. Another patent for compounds for use in treatment of mucositis received formal notice of Intent to Grant from the U.S. Patent & Trademark Office in March 2017.
Dr. Menon has a very impressive resume.
Taken from IPIX website.
Go Leo & IPIX!
KRISHNA MENON, PHD, VMD
Chief Scientific Officer, President of Research, and Board of Directors
Dr. Menon is a co-founder of Innovation, serving as Chief Scientific Officer, and Board Member. He is a leading pharmaceutical scientist with over 30 years of drug development experience in academia and industry. Prior to Innovation, Dr. Menon served at Eli Lilly as Group Leader, Cancer In Vivo Research and Clinical Development. While there, Dr. Menon played an integral role in lead selection and pre-clinical development of Gemzar and Alimta, two blockbuster oncology drugs. He was awarded Eli Lilly’s prestigious President’s Recognition Award. Earlier in his professional career, he held research scientist positions at Miles Laboratories and Dana Farber Cancer Research Institute. Dr. Menon is a trained veterinary surgeon (VMD) and holds a PhD (Pharmacology) from Kerala University.
petemantx,
I agree 100%. If there are new investors reading this board they might be pretty confused.
They only need visit IPIX website and do their own DD to see that this small company is going to be a big player someday.
Go Leo & IPIX!
Next three months are going to be ticklish trading times for IPIX as one never knows when the first of a possible host of important news releases will be put out; B-UP deal, B-OM secondary end points, partner deal for a complete platform, P results, further results of K trial to date, money influx from a reputable lender on very favorable terms to IPIX, pill formulation success for P or K, gel success for B-UPS, breakthrough therapy designation, fast turnaround by FDA for further trials, etc.
I will be sitting back watching and enjoying the show. Ticket fully punched and waiting for the big ending to this trader's game we have been playing the last few years.
For new investors, do the research on the science behind our products and forego the dire warnings that cannot be supported by scientific fact. Also, what happened years ago has no bearing on what is happening today and those arguments are being used because that is all those trying to keep the price down have left to try and muddy the puddle of facts.
centillion,
So well put!
Go Leo & IPIX!
You answered your own question... "What do we expect trading on the pinks?" It's not whether Leo did this or didn't do that, it's not what Mako has done or hasn't done ether. You said it, "You are what you trade on"... If you don't like your choice of place to invest then don't look to point fingers outward to blame something or someone else, simply choose again. For you can only blame yourself for your suffering, it was you who made the choice. Stop the blame game!
George,
You have been right a lot with timing/information and I am getting excited. Lets hope you are right on this one too...
2018
Go Leo & IPIX!
sox040713,
As always, great post and a good reminder!
Go Leo & IPIX!
BP's interests in the Big Three
"To advance our pipeline in an expeditious manner, this year we placed an emphasis on partnering—actively engaging global and regional pharmaceutical companies interested in licensing our novel drug candidates. These efforts have led to highly productive, mature (late-phase, ongoing) discussions, with multiple pharmaceutical companies, which we hope will bear fruit in the coming year." - CEO Letter to Shareholders
"We had said that confidential disclosure agreements have been signed with several pharmas interested in our drug candidates; to some, they're interested in one compound. Others have requested information on a combination of Brilacidin and Kevetrin and Prurisol."
https://seekingalpha.com/article/4080068-innovation-pharmaceuticals-ipix-ceo-leo-ehrlich-q3-2017-results-earnings-call-transcript
B-OM
“Formal collaboration with pharmaceutical companies that have expressed an interest in partnering Brilacidin-OM may well assist further with expediting the drug candidate’s development timetable. Some of these partnering conversations have matured to the point of potentially structuring mutually beneficial licensing agreements, pending the final Phase 2 study results.”
http://www.ipharminc.com/press-release/2017/11/16/innovation-pharmaceuticals-offers-perspectives-on-brilacidin-as-a-potential-preventative-treatment-for-oral-mucositis-in-head-and-neck-cancer-patients
B-UP
"We've actively engaged with multiple large pharmas, who have expressed an interest in Brilacidin inflammatory bowel disease. The pharma industry is quite interested in pursuing novel IBD therapies one of the more active therapeutic areas when it comes to dealmaking."
https://seekingalpha.com/article/4080068-innovation-pharmaceuticals-ipix-ceo-leo-ehrlich-q3-2017-results-earnings-call-transcript
Prurisol
"We have entered into multiple non-disclosure agreements with large pharmaceutical companies that enable us to continue ongoing discussions regarding potential partnering should the trial results support such a relationship."
https://www.sec.gov/Archives/edgar/data/1355250/000147793217004400/ipix_10k.htm
Kevetrin
"What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,"
http://www.ipharminc.com/press-release/2017/9/14/innovation-pharmaceuticals-opens-new-clinical-site-for-novel-p53-drug-candidate-in-phase-2-ovarian-cancer-trial-1
Detonate,
No problem and I am glad we have the same opinion of IPIX! I have been in for about the same amount of time.
IMO, The sky is the limit for IPIX once we get out of the OTC and into the big boy/girl board (nasdaq) which will hopefully happen this year. This in my mind will allow us to see the real potential of this stock.
I have said it numerous times in the past and I will say it again.
Thank you to all of the people on this board who post factual information. I have no science back ground and it is important for me to read you(r) understanding of IPIX science.
Go Leo & IPIX!
I honestly don't understand your reply. It is so vague I could answer you in a hundred different ways and I am going to save myself the effort.
I personally cannot refute the facts and the facts indicate 2018 is going to be a very big year for IPIX.
Check it out, all of the facts are on this website. http://www.ipharminc.com/
Good Luck to all longs in 2018 and Happy New Year!
Go Leo & IPIX!
BioTechMaven,
Awesome post and I could not agree with you more.
2018 will be our year - IPIX's year!
Go Leo & IPIX!
On the cusp of 2018 and exciting times ahead I hope for IPIX. I’m in Cape Town with my daughter and the boyfriend. He passes muster, ROTC, like I was. Could do with chewing his food with his mouth closed though!
What was not recently lost on me was reading between the lines in the holiday email. Namely, scroll down to the last few paragraphs and emphasis on partnership discussions. Now, either we have a really obtuse CEO, or we have one that has continually sent signals that portend to moments that in majority come true. My simple interpretation, and look, I’m damn biased here with a few ranches (Sacramento Valley valuations) bet on IPIX. I’m overweighted to the point of moderate discomfort and I’m also about 30% in the red after some recent accumulations over the last few months. With that said, and call me stupid, but I’m as confident as ever that IPIX is on the cusp of securing important partnerships and digging themselves out of a hole and into the BIG LEAGUES.
I’m super attuned to Brilacidin OM potential. Show me strong secondary endpoints evidence and FDA Breakthrough imo is all but a formality, as would be a partnership.
Kevetrin is revealing itself like few understand as it reveals MOA complexities that are beyond my brain but one look no further at the p53 competitive analysis to see that 3-4 other p53 companies are ALL partnered off with nasty side effects, questionable efficacy, and no oral delivery. A partnership for Kevetrin, seems yet another inevitability in a voracious oncology landscape.
Talk to me about Prurisol. If she delivers, not only will she drop the jaws of management who have always nudged her in PRs by saying the ‘darkhorse’ but a passable result on par with Otezla’s first phase 2 trials, and big pharma won’t hesitate to jump in for a run at the oral grail.
Brilacidin IBD is the one where coming out of a small PoC where I’d love to see a pharma pony up and dive in. Big Pharmas run small PoC trials all the time, all the time. And would love to see one dive In with gusto.
So, 3-4 assets all partnerable. IF we make it to 3Q with NO partner then I’m picking up my red phone in my home office and calling Beverley. But until then, I’m excited and expectant that one day I’ll be on the 19th at Torrey and check my phone over a marg and see what should be the start of a new era.
Robben Island tomorrow, Krueger NP om Tuesday. Santa Barbara by Saturday.
Happy New Year
George,
Great post!
Thank you,
Go Leo & IPIX!
biopa,
I can't agree more! Jan 8 2018...
Go Leo & IPIX!
We all get caught up in the day to day action surrounding IPIX. I think it should have been more visible that nothing substantial was going to happen until January. With the new tax laws taking effect there are many benefits to Pharma companies to wait until 2018. It should start to brake loose in January after the accountants determine the most efficient way to structure and pay for new deals. IPIX will be one of them
georgejjl,
Can't wait. This time is not coming quick enough for me.
Go Leo & IPIX!
Biotech Showcase 2018
January 8, 2018
Date: Monday, January 8, 2018
Time: 4:00 PM PST
Track: Yosemite - C (Ballroom Level)
Innovation Pharmaceuticals will be presenting a corporate overview at the 10th Annual 2018 Biotech Showcase in San Francisco. The senior management team will be available to participate in one-on-one meetings at select times on January 8th and 9th. Conference attendees who are interested in scheduling a meeting are encouraged to sign up through the conference's portal, at the link provided below, or by emailing Innovation directly at info@ipharminc.com.
http://www.ipharminc.com/new-events-and-presentations/2017/11/20/biotech-showcase-2018
Good luck and GOD bless,
George
DaubersUP,
I am feeling it too. Seriously, I have this unbelievable urge to buy more IPIX.
Go Leo & IPIX!
Agree. And IPIX brought us to a place where we can have a partner for 3 drugs and 5 indications at any time.
We just need competition. The more BPs interested the quicker term sheets are delivered. However, maybe they already know their suitor....we will find out.
WILD_4_IPIX,
Desperate times call for desperate measures!
This January will be exciting times for IPIX and us longs.
Go Leo & IPIX!